If LDL-C is "normal", am I safe?

Not necessarily. LDL-C measures mass, not particle number. If triglycerides are high and HDL low (Trig/HDL >1.5), phenotype B and high ApoB are very likely — higher risk even at "normal" LDL-C. Ask for ApoB.

Is a statin the only answer?

Statins are clinically effective and justified in specific situations — that's an individual clinical decision. But lifestyle (nutrition, movement, sleep, insulin sensitivity) often moves particle number, size and inflammatory context as much or more than a drug alone, and works synergistically with statins.

Is Lp(a) "treatable"?

Lifestyle affects Lp(a) minimally. With high Lp(a) the focus shifts to aggressive control of the other levers (LDL/ApoB, hs-CRP, blood pressure, smoking). Novel RNA-based drugs are in clinical trials.

Why do homocysteine and fibrinogen matter?

Homocysteine damages the endothelium directly — high levels accelerate atherosclerosis even at low LDL. Fibrinogen raises clotting and thrombus risk. Both are modifiable (B-vitamins, lifestyle, stress management) and belong on any thorough lipid panel.

Should I get a coronary artery calcium (CAC) scan?

From age 40, especially with family risk or uncertainty, CAC is one of the most informative single tests — it shows whether atherosclerosis has already started. Score 0 = very low 10-year risk; >100 = aggressive secondary prevention is indicated.

Miks LDL üksi ei ole piisav marker?

LDL mõõdab kolesterooli hulka, aga mitte osakeste arvu ega tihedust. Kahel inimesel sama LDL-iga võib olla kardiovaskulaarrisk 3× erinev, kui ühel on väikesed tihedad LDL-osakesed (B-fenotüüp) ja teisel suured kohevad (A-fenotüüp). ApoB mõõdab osakeste arvu — see on täpsem.

Mis on ApoB ja miks see loeb?

ApoB (apolipoproteiin B) on valk igal aterogeensel osakesel (LDL, VLDL, IDL, Lp(a)). Üks osake = üks ApoB. ApoB > 90 mg/dl on kõrge risk sõltumata LDL-ist. See on tänapäeva riskihinnangu kuldstandard (ESC 2019 juhised).

Millal peaks laske mõõta Lp(a)?

Vähemalt ÜKS kord elu jooksul igal täiskasvanul (ESC 2019, EAS 2022). Lp(a) on geneetiline — kui isal või emal oli varajane infarkt ( 50 mg/dl) tõstab südameinfarkti riski 2–3×.

Kas madal-süsivesikuline dieet tõstab LDL-i ja kas see on ohtlik?

Ligikaudu 30%-l inimestest tõuseb LDL keto/low-carbil („hyper-responder" fenotüüp). Aga sageli tõuseb SUURTE osakeste LDL-A, mitte väikeste tihedatega LDL-B — riskiprofiil võib paraneda (kõrgem HDL, madalam trig). Vaja on ApoB ja tervikpilti, mitte üksnes LDL-i.

Kas statin on ainuke lahendus kõrge kolesterooli puhul?

Ei — aga see on üks tõenduspõhiseimaid ravimeid. Alternatiivid ja täiendused: bergamott, punase riisi pärm (naturaalne statin), niatsiin, oomega-3, kiudained, taimestanoolid. Ravim valik sõltub baasjoonest, riskist, taluvusest. Elustiil on alati alus.

Millised toidud alandavad LDL-i tõenduspõhiselt?

Lahustuvad kiudained (kaerakleepud, chia, oad), kreeka pähklid ja mandlid, oliiviõli ja avokaado, taimestanoolid (2 g/päevas → 10% LDL langus), rasvane kala (oomega-3), rohelised köögiviljad. Portfoolio-dieet vähendab LDL-i keskmiselt 30%.

Kas munad tõstavad kolesterooli?

Enamikul inimestest — ei. Toidukolesterool on ~15% vere kolesteroolist; keha reguleerib maksast sünteesi. 1–3 muna päevas on suurel enamusel ohutu. Erand: „hyper-responder" fenotüüp (25% inimestest) — kontrolli labor 6 nädala pärast.

Mis on „aterogeenne diabeetiline düslipideemia"?

Insuliiniresistentsuse tüüpiline pilt: kõrged triglütseriidid, madal HDL, väikesed tihedad LDL-osakesed (B-fenotüüp), tõusnud ApoB. LDL üksi võib olla „normis", aga risk on kõrge. See on peamine põhjus miks IR-i lehe ja Kolesterooli lehe teemad on seotud.

Kas oomega-3 lisandid vähendavad kardiovaskulaarriski?

EPA-le keskendunud preparaadid (nt icosapent) näitasid tugevat efekti (REDUCE-IT uuring, 25% MACE vähenemine). Segastest EPA+DHA preparaatidest on tõendus segasem. Suurte annuste (2–4 g/päev) puhul alati arstiga.

Millal peaks laske mõõta homotsüsteiini?

Kui perekonnas on varajane ateroskleroos, tromboosid, aju-insult; kui on B12/folaadi puudus, hüpotüreoos, teatavaid geneetilisi variantide (MTHFR) kahtlus. Homotsüsteiin > 10 µmol/l on kardiovaskulaarne riskitegur; > 15 µmol/l — selge patoloogia.

Health monitoring

Heart & vascular health

Cholesterol, ApoB and the lipoprotein profile

"High cholesterol" is one of the most over- and under-interpreted lab results in modern medicine. What clinically matters is not total cholesterol or even LDL-C alone, but the particle count (ApoB), their size (phenotype A vs B), Lp(a) and inflammatory markers such as hs-CRP, homocysteine and fibrinogen.

ApoB > LDL-C — measures the actual particle count
Small dense LDL (phenotype B) is many times more dangerous
Lp(a), hs-CRP, homocysteine, fibrinogen — often forgotten, clinically decisive

Book a consultation 5 tests for metabolic health

Arst vaatab laiendatud lipiidipaneeli tulemusi

What is cholesterol and why the standard panel misses half the picture

Cholesterol is not a "bad substance". It is the raw material for every cell membrane, for hormones (testosterone, oestrogen, cortisol) and for vitamin D. The liver produces ~80% of circulating cholesterol; only ~20% comes from food.

Water-insoluble cholesterol is transported in the blood inside lipoproteins — LDL, VLDL, IDL, HDL and Lp(a). Every such particle carries apolipoprotein B (ApoB) on its surface, except HDL which carries ApoA. Measuring ApoB gives a direct count of potentially atherogenic particles — something traditional "LDL cholesterol" (in grams) cannot do.

Two people with the same LDL-C (say 3.5 mmol/L) can have very different risk: one carries large, fluffy, low-count LDL particles (phenotype A — low risk), the other many small, dense LDL particles (phenotype B — high risk). Same mass, very different particle behaviour.

Clinical signs and red-flag profile

Trig/HDL ratio >1.5 — indirect sign of phenotype B and insulin resistance
Family history of early heart attack (men <55, women <65)
Diagnosed familial hypercholesterolaemia (FH)
Xanthelasma (yellow eyelid plaques), arcus corneae before age 50
Vascular thickening on carotid or abdominal ultrasound
Metabolic syndrome: abdominal fat + high BP + insulin resistance
Chronic inflammatory state (autoimmune, periodontitis, IBD)
Smoking and chronic stress — accelerate atherosclerosis even at "normal" LDL

Why ApoB is better than LDL-C

An atherosclerotic plaque forms when an ApoB-carrying particle crosses the endothelium and gets stuck. What counts is how many particles are at the door — not how many grams of cholesterol they carry. Every LDL/VLDL/IDL/Lp(a) particle carries one ApoB molecule — so ApoB = direct particle count.

Large studies (Sniderman, Circulation 2019; INTERHEART) show ApoB predicts cardiovascular events more accurately than LDL-C. This especially matters in discordance: someone with "normal" LDL-C but high ApoB is still at high risk.

Particle size: phenotype A vs B

Phenotype A — large, fluffy LDL, fewer particles, lower risk
Phenotype B — small, dense LDL (sdLDL), more particles, higher risk
Phenotype B arises with insulin resistance, high triglycerides and low HDL
Trig/HDL >1.5 (mmol/L) or >3.5 (mg/dL) = strong indirect sign of phenotype B
sdLDL more easily enters the endothelium and is more oxidation-prone — hence more atherogenic

Lp(a) — the genetic risk factor rarely tested

Lp(a) is an LDL-like particle with apo(a) attached. Its level is 80–90% genetic and stays roughly constant for life. High Lp(a) (>50 mg/dL or >125 nmol/L) raises heart-attack risk 2–3× and markedly increases aortic-valve stenosis risk.

Lp(a) should be measured at least once in every adult — especially with a family history of early heart disease. Lifestyle affects Lp(a) minimally; therapy is currently limited (apheresis; RNA-based agents in development).

The "silent" inflammation: hs-CRP, homocysteine, fibrinogen

hs-CRP >2 mg/L — 2× higher CV risk even at normal LDL (Ridker, JUPITER)
Homocysteine >10 μmol/L — vascular toxin damaging endothelium. Lowered by B12, folate, B6, betaine
Fibrinogen >4 g/L — coagulation over-activation, accelerates thrombus formation
Lp-PLA2 (in select labs) — specifically vascular inflammation
GGT and ferritin — indirect liver and systemic-inflammation markers

Four pillars to improve the lipid profile

A statin is one tool. Before, alongside and after sits lifestyle, which directly changes particle number, size and inflammatory context.

Nutrition

Cut refined carbs and liquid sugar — the main drivers of triglycerides and phenotype B. Fibre (30 g+/day), omega-3, monounsaturated fats (olive oil, avocado, nuts). Losing 5–10% of body weight often drops ApoB by 15–25%.

Insulin sensitivity

Phenotype B and high triglycerides are 90% downstream of insulin resistance. Lower insulin — eating window 8–10 h, strength training, sleep — and the lipid profile improves more than with drugs alone.

Movement

Strength 2–3×/week + aerobic (Zone 2, 150 min/week) raises HDL, lowers triglycerides, shifts phenotype B → A and lowers hs-CRP. Movement directly changes particle size.

Sleep, stress, no smoking

Chronic sleep loss raises cortisol, glucose, triglycerides and hs-CRP. Smoking lowers HDL, oxidises LDL and dramatically accelerates atherosclerosis. Stress management lowers fibrinogen and clotting.

Supplements to support lipids and vascular health

Supplements don't replace statins when clinically indicated — that decision belongs with your doctor. But several complement lifestyle effectively and move markers statins don't touch.

Omega-3 (EPA/DHA, 2–4 g/day) — lowers triglycerides 20–30%, reduces inflammation
Berberine — lowers LDL-C and ApoB ~15%, improves insulin sensitivity; watch drug interactions
Red-yeast rice (monacolin K) — statin-like action; don't combine with a statin
B12, folate (methyl forms), B6, betaine (TMG) — lower homocysteine
Vitamin K2 (MK-7) — routes calcium into bone, not arteries (paired with D)
CoQ10 (ubiquinol) — mitochondrial support, especially on a statin
Nattokinase — lowers fibrinogen with fibrinolytic action (data emerging)
Plant sterols / fibre (psyllium) — reduce cholesterol absorption in the gut

Fasting and the lipid profile

Time-restricted eating and periodic fasting lower triglycerides, shift LDL towards phenotype A and reduce ApoB — indirectly via improved insulin sensitivity.

Tinsley et al. (2019, Am J Clin Nutr): 16:8 combined with resistance training improved the lipid profile and body composition in adults with excess weight, including triglycerides and fat mass.

Not appropriate in pregnancy, lactation, eating-disorder history or on certain medications (insulin, sulfonylureas) without supervision.

See the study (Am J Clin Nutr)

Expanded lipid panel — what to ask for

ApoB — direct atherogenic-particle count (target <0.9 g/L, high risk <0.65)
Lp(a) — at least once in life (target <30 mg/dL / <75 nmol/L)
LDL-C, HDL-C, triglycerides, total cholesterol (standard panel)
Trig / HDL ratio — indirect phenotype B and IR marker
Non-HDL cholesterol — all atherogenic particles combined
hs-CRP — vascular inflammation (target <1 mg/L)
Homocysteine (target <8 μmol/L)
Fibrinogen (target <3.5 g/L)
Fasting insulin and HOMA-IR — root cause of phenotype B
Thyroid (TSH, free T3) — hypothyroidism raises LDL
Vitamin D, ferritin — systemic context
Coronary artery calcium score (CAC) from age 40 — direct plaque burden

Want to know your real cardiac risk?

In the consultation we review your expanded lipid panel (ApoB, Lp(a), hs-CRP, homocysteine, fibrinogen), the CAC score and build an individual plan you can discuss with your GP and/or cardiologist.

Book a consultation Pay later or in instalments — via Montonio at checkout

Dr Sergey Saadi — preventive medicine physician

Address root causes — three steps with Dr Saadi

Dr Sergey Saadi is a preventive medicine physician with 15+ years of practice, specializing in metabolic health, weight management and the root causes of chronic metabolic dysfunction. Pick the step that matches your current question.

Step 1
Start here€490
Individual consultation (45 min)
We review your labs, symptoms and history. You leave with a clear picture of what's happening in your body and which next steps fit you — with reasoning, not generic advice.
Book a consultation
Step 2
Structured supportfrom €1,900
Guided monitoring (30, 60 or 90 days)
Three to four consultations + concierge support on Telegram (Mon–Fri). A systemic plan for nutrition, sleep, training load and, where needed, medications and supplements — a longer-term format for managing metabolic health with a physician.
See monitoring packages
Step 3
Deep dive€490
TellmeGen Advanced genetic test
400+ health markers and 700,000+ SNPs. Lifetime access to your report (updates as science advances). Includes a 45-minute physician interpretation.
Explore the test

Lipiidiprofiili sihttasemed

Sihtväärtused sõltuvad kardiovaskulaarsest riskist (ESC 2019, EAS 2022)

Marker	Madal risk	Mõõdukas / kõrge risk	Väga kõrge risk
LDL-kolesterool	< 3,0 mmol/l	< 2,6 mmol/l	< 1,4 mmol/l
ApoB	< 100 mg/dl	< 80 mg/dl	< 65 mg/dl
Triglütseriidid	< 1,7 mmol/l	< 1,5 mmol/l	< 1,5 mmol/l
HDL-kolesterool (M / N)	> 1,0 / > 1,2 mmol/l	sama	sama
Lp(a)	< 30 mg/dl (< 75 nmol/l)	sama	sama
Non-HDL kolesterool	< 3,8 mmol/l	< 3,4 mmol/l	< 2,2 mmol/l
Homotsüsteiin	< 10 µmol/l	< 10 µmol/l	< 10 µmol/l

Väga kõrge risk = varasem infarkt/insult, diabeet + kahjustus, krooniline neerukahjustus, familiaalne hüperkolesteroleemia. ApoB on täpsem kui LDL üksi.

Frequently asked questions

Go deeper: related materials

Articles

Guides

Webinars

All webinars

Courses

All courses

Dr Sergey Saadi — expert in advanced lipidology and metabolic health

Dr Sergey Saadi is a physician with over 15 years of clinical practice.

Clinical approach: ApoB + Lp(a) + hs-CRP + homocysteine + fibrinogen — not just LDL-C
Regular speaker in media and in clinician training
Author of "Dangerous secrets of blood sugar" (Varrak)

Alternative path

Go deeper: lipidology and cardiovascular webinars

Recorded webinars on ApoB, lipoproteins and cardiovascular risk assessment — with Dr Saadi.

See webinars

Legal notice and limitation of liability

The content of this website and all published materials (articles, guides, PDFs, recipes, recommendations, video and audio) is provided for educational and informational purposes only. It is not medical advice, a diagnosis or a treatment recommendation for any specific person.
Reading, downloading or using this content does not create a doctor–patient relationship and does not replace a consultation with your physician, dietitian, pharmacist or other healthcare professional.
The target values, doses, supplements, protocols and schedules shown are general references to scientific literature. Your individual health condition, medications and contraindications may make these recommendations unsuitable or unsafe for you.
Before changing your diet, exercise, fasting, cold therapy, supplements or medications, consult your physician — especially if you have diabetes, cardiovascular disease, high blood pressure, thyroid disorder, kidney or liver disease, an eating disorder, are pregnant, breastfeeding or under 18.
Emergency: for acute symptoms (chest pain, shortness of breath, loss of consciousness, severe headache, neurological symptoms) call 112. For non-urgent questions, the family doctor advice line 1220.
Third-party products, brands and devices mentioned are provided for educational purposes only — this is not an endorsement or recommendation to purchase any specific product. Some links may be affiliate links; they do not change the price for you.
The author and OÜ Süsivesik accept no liability for direct or indirect damages arising from use of, reliance on or interpretation of this content. Use of these materials is at the reader's own risk.

This page is educational and general. It is not personal medical advice, a diagnosis or a treatment plan. Discuss changes with your doctor.